Loading…
Trinity Biotech plc is projected to rise to $11.35 by 2027, a +2% move from its current price of $11.13. TRIB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $9.85 | $11.12 | $12.54 | -0.09% |
| Aug 6 | $9.37 | $11.11 | $13.17 | -0.18% |
| Aug 7 | $9.01 | $11.10 | $13.67 | -0.26% |
| Aug 8 | $8.71 | $11.09 | $14.11 | -0.35% |
| Aug 9 | $8.46 | $11.08 | $14.50 | -0.44% |
| Aug 10 | $8.24 | $11.07 | $14.87 | -0.53% |
| Aug 11 | $8.04 | $11.06 | $15.21 | -0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.04 | $11.06 | $15.21 | -0.61% |
| Week 2 | $7.00 | $10.99 | $17.25 | -1.23% |
| Week 3 | $6.29 | $10.92 | $18.97 | -1.83% |
| Week 4 | $5.74 | $10.85 | $20.53 | -2.44% |
| Week 5 | $5.29 | $10.79 | $22.00 | -3.03% |
| Week 6 | $4.91 | $10.72 | $23.41 | -3.63% |
| Week 7 | $4.58 | $10.66 | $24.77 | -4.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Trinity Biotech plc is a healthcare company that acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren
ess syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners.
Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Trinity Biotech plc (TRIB) is currently priced at $12.45 with a market cap of $8.4M and a rank of 4921. The near-term technical picture shows a wide 30-day price range and a neutral sentiment, with RSI14 at 100 and moving averages at SMA50 $0.7008 and SMA200 $0.7913. Support is noted at $0.34 and resistance at $9.15, indicating notable near-term levels to observe.
The multi-year forecast paints a path of upside potential, with the 2026–2050 figures showing varying average prices and ROIs, including bullish years such as 2029, 2030, 2034, 2035, 2040, and 2050, culminating in a 2050 average of $32.71 and a maximum forecast of $75.22.
A major floor 97.0% below — a decisive break under it would weaken the trend.
The nearest floor, 96.9% below — buyers have tended to step in here.
The nearest ceiling, 18.5% above — a clean break opens room to run.
A major ceiling 90.7% above — clearing it would confirm fresh momentum.
Key TRIB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRIB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.83 | Sell | $11.31 | Sell |
| MA 10 | $8.63 | Buy | $9.13 | Buy |
| MA 20 | $4.50 | Buy | $6.26 | Buy |
| MA 50 | $2.15 | Buy | $3.33 | Buy |
| MA 100 | $1.40 | Buy | $2.09 | Buy |
| MA 200 | $1.14 | Buy | $1.48 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 81.20 | Sell |
| Stoch RSI (14) | 74.95 | Neutral |
| CCI (20) | 95.37 | Neutral |
| Williams %R (14) | -12.30 | Info |
| MACD (12,26,9) | 1.08 | Buy |
| ROC (12) | 3122.22 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 87.70 | Sell |
| TRIX (15) | 21.51 | Buy |
| Awesome (5,34) | 8.98 | Buy |
| Ultimate (7,14,28) | 75.26 | Sell |
| Momentum (10) | 11.26 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 14.00 | Sell |
| ADX (14) | 53.18 | Buy |
| ATR (14) | 0.80 | Info |
The near-term picture shows a 30-day range from $5.55 to $27.91, with RSI14 at 100 and sentiment labeled NEUTRAL. The stock’s technical setup includes SMA50 at $0.7008 and SMA200 at $0.7913, with defined support at $0.34 and resistance at $9.15.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.34 | $11.13 | $11.29 | 0% | Neutral | |
| $8.27 | $11.35 | $16.84 | +2% | Neutral | |
| $9.99 | $14.58 | $23.07 | +31% | Bullish | |
| $10.43 | $16.05 | $26.68 | +44% | Bullish | |
| $10.35 | $16.69 | $28.89 | +50% | Bullish | |
| $8.49 | $14.31 | $25.65 | +29% | Bullish | |
| $8.27 | $14.54 | $26.89 | +31% | Bullish | |
| $8.53 | $15.62 | $29.69 | +40% | Bullish | |
| $9.78 | $18.63 | $36.31 | +67% | Bullish | |
| $11.85 | $23.47 | $46.81 | +111% | Bullish | |
| $13.21 | $29.35 | $64.36 | +164% | Bullish | |
| $16.34 | $36.31 | $83.51 | +226% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.34 | $11.13 | $12.73 | +0.00% |
| September 2026 | $8.30 | $10.09 | $12.79 | -9.34% |
| October 2026 | $8.33 | $10.27 | $13.29 | +1.79% |
| November 2026 | $7.54 | $9.40 | $12.37 | -8.42% |
| December 2026 | $6.72 | $8.46 | $11.29 | -10.03% |
Click any year to see its month-by-month TRIB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TRIB to range from $0.34 to $11.29 through 2026. The $11.13 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TRIB price prediction for 2027 points to an average of $11.35 (low $8.27, high $16.84) — a potential gain of +2% on today's $11.13. A consolidation phase looks the most probable path here.
In 2028, TRIB is projected to trade between $9.99 and $23.07, averaging $14.58 — a potential gain of +31% from today's $11.13. That is up +28% on the projected 2027 average. Momentum favours further upside here.
Trinity Biotech plc's 2029 outlook centres on $16.05, within a $10.43 to $26.68 range. That is up +10% on the projected 2028 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, TRIB could reach as high as $28.89, with a base case around $16.69 and support toward $10.35 — roughly +50% from $11.13. Momentum favours further upside here.
Expect TRIB to range from $8.49 to $25.65 through 2031. The $14.31 average target implies a +29% move from current prices. That is -14% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The TRIB price prediction for 2032 points to an average of $14.54 (low $8.27, high $26.89) — a potential gain of +31% on today's $11.13. Momentum favours further upside here.
In 2033, TRIB is projected to trade between $8.53 and $29.69, averaging $15.62 — a potential gain of +40% from today's $11.13. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Trinity Biotech plc's 2034 outlook centres on $18.63, within a $9.78 to $36.31 range. That is up +19% on the projected 2033 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2035, TRIB could reach as high as $46.81, with a base case around $23.47 and support toward $11.85 — roughly +111% from $11.13. Buyers look set to stay in control over this stretch.
Expect TRIB to range from $13.21 to $64.36 through 2040. The $29.35 average target implies a +164% move from current prices. That is up +25% on the projected 2035 average. Momentum favours further upside here.
The TRIB price prediction for 2050 points to an average of $36.31 (low $16.34, high $83.51) — a potential gain of +226% on today's $11.13. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRIB today (≈ 89.88764 TRIB) could be worth
$3,263.55
+$2,263.55 (+226%) by 2050 · US Dollar
Based on the average projected TRIB price of $36.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRIBwould be worth at today's price.
$1,000 invested in TRIB on Jul 31, 2025 (≈ 1,449.275367 TRIB) would be worth
$16,123.19
+$15,123.19 (+1512.3%) today · 16.12× · US Dollar
Based on a TRIB entry price of $0.69 vs. today's $11.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.45 | $1,316.57 | +31.7% |
| 1 month ago | $0.36 | $30,902.78 | +2990.3% |
| 3 months ago | $0.61 | $18,237.7 | +1723.8% |
| 6 months ago | $0.82 | $13,567.07 | +1256.7% |
| 1 year ago | $0.69 | $16,123.19 | +1512.3% |
| All time (5.0y) ago | $11.7 | $950.85 | -4.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRIB forecast.
Our base-case forecast reaches $22.00 around 2035.
Implied market cap at $22.00: $14.85M
The long-range forecast outlines a gradual upside across years. In 2026 the min is $0.34, the avg is $12.45, the max is $12.52 with ROI 0% and sentiment NEUTRAL. In 2027 the min is $8.53, the avg is $11.72, the max is $17.40 with ROI -5.9% and sentiment NEUTRAL.
In 2028 the min is $9.53, the avg is $13.92, the max is $22.05 with ROI 11.8% and sentiment NEUTRAL. In 2029 the min is $10.43, the avg is $16.06, the max is $26.71 with ROI 29% and sentiment BULLISH. In 2030 the min is $10.55, the avg is $17.03, the max is $29.50 with ROI 36.8% and sentiment BULLISH.
In 2031 the min is $8.45, the avg is $14.26, the max is $25.59 with ROI 14.6% and sentiment NEUTRAL. In 2032 the min is $8.16, the avg is $14.37, the max is $26.58 with ROI 15.4% and sentiment NEUTRAL. In 2033 the min is $7.96, the avg is $14.59, the max is $27.74 with ROI 17.2% and sentiment NEUTRAL.
In 2034 the min is $8.34, the avg is $15.90, the max is $31.01 with ROI 27.7% and sentiment BULLISH. In 2035 the min is $10.97, the avg is $21.74, the max is $43.37 with ROI 74.6% and sentiment BULLISH. In 2040 the min is $10.86, the avg is $24.14, the max is $52.95 with ROI 93.9% and sentiment BULLISH.
In 2050 the min is $14.72, the avg is $32.71, the max is $75.22 with ROI 162.7% and sentiment BULLISH.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $10.55, an avg of $17.03, and a max of $29.50, with ROI 36.8% and sentiment BULLISH.
The forecast includes bullish years (e.g., 2029 with avg $16.06 and ROI 29%) and 2050 with avg $32.71 and ROI 162.7%, but there are neutral/negative periods (e.g., 2027 ROI -5.9%). These are estimates, not guarantees.
The 2050 maximum forecast is $75.22, which would exceed $50, suggesting a path to $50 is within the modeled maximum, but it is not guaranteed.
The 30-day range is $5.55 to $27.91.
Current price is $12.45 and market cap is $8.4M.
Trinity Biotech plc Community Discussion
0Share your Trinity Biotech plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.